Skip to content
Agentic OS
Menu

Intelligence / Healthtech / New Clinical Trials / Zi Diligence Biocenter

Clinicaltrial registered6 Nov 2026

Zi Diligence Biocenter

6 Nov 2026: Trial registered · An Open-label, Randomized, Single Oral Dose, Two-period, Two-sequence, Two-way, Crossover Bioequivalence Study on Healthy Adult Male Participants Under Fed Conditions to Compare, Test Product Palbociclib-EVAPHARMA 125 mg Hard Gelatin Capsule, Versus the Reference Product Ibrance™125 mg Capsules. Recorded in the ClinicalTrials.gov (US National Library of Medicine).

View the source record

Posted
6 Nov 2026
Title
An Open-label, Randomized, Single Oral Dose, Two-period, Two-sequence, Two-way, Crossover Bioequivalence Study on Healthy Adult Male Participants Under Fed Conditions to Compare, Test Product Palbociclib-EVAPHARMA 125 mg Hard Gelatin Capsule, Versus the Reference Product Ibrance™125 mg Capsules
Conditions
Bioequivalence, Male
Phase
Phase 1
Study Type
Interventional
Status
Completed
Countries
Egypt
Country
Egypt
Reference
NCT07922564
Location
Egypt
What this signal means

A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.

  1. United States leads with 192 of 777, then China (171).
  2. 777 added in the 30 days to 18 Nov 2026.
Reach them with AOS

Find the decision makers at Zi Diligence Biocenter

AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.

Start free

Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.